Benzodiazepines versus placebo for panic disorder in adults
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Panic disorder is characterised by recurrent unexpected panic attacks consisting of a wave of intense fear that reaches a peak within a few minutes. Panic disorder is a common disorder, with an estimated lifetime prevalence of 1% to 5% in the general population and a 7% to 10% prevalence in primary care settings. Its aetiology is not fully understood and is probably heterogeneous.Panic disorder is treated with psychological and pharmacological interventions, often used in combination. Although benzodiazepines are frequently used in the treatment of panic disorder, guidelines recommend antidepressants, mainly selective serotonin reuptake inhibitors (SSRIs), as first-line treatment for panic disorder, particularly due to their lower incidence of dependence and withdrawal reaction when compared to benzodiazepines. Despite these recommendations, benzodiazepines are widely used in the treatment of panic disorder, probably because of their rapid onset of action. OBJECTIVES: To assess the efficacy and acceptability of benzodiazepines versus placebo in the treatment of panic disorder with or without agoraphobia in adults. SEARCH METHODS: We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR Studies and References), the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1950-), Embase (1974-), and PsycINFO (1967-) up to 29 May 2018. We handsearched reference lists of relevant papers and previous systematic reviews. We contacted experts in the field for supplemental data. SELECTION CRITERIA: All double-blind (blinding of patients and personnel) controlled trials randomising adults with panic disorder with or without agoraphobia to benzodiazepine or placebo. DATA COLLECTION AND ANALYSIS: Two review authors independently checked the eligibility of studies and extracted data using a standardised form. Data were then entered data into Review Manager 5 using a double-check procedure. Information extracted included study characteristics, participant characteristics, intervention details, settings, and outcome measures in terms of efficacy, acceptability, and tolerability. MAIN RESULTS: We included 24 studies in the review with a total of 4233 participants, of which 2124 were randomised to benzodiazepines and 1475 to placebo. The remaining 634 participants were randomised to other active treatments in three-arm trials. We assessed the overall methodological quality of the included studies as poor. We rated all studies as at unclear risk of bias in at least three domains. In addition, we judged 20 of the 24 included studies as having a high risk of bias in at least one domain.Two primary outcomes of efficacy and acceptability showed a possible advantage of benzodiazepines over placebo. The estimated risk ratio (RR) for a response to treatment was 1.65 (95% confidence interval (CI) 1.39 to 1.96) in favour of benzodiazepines, which corresponds to an estimated number needed to treat for an additional beneficial outcome (NNTB) of 4 (95% CI 3 to 7). The dropout rate was lower among participants treated with benzodiazepines (RR 0.50, 95% CI 0.39 to 0.64); the estimated NNTB was 6 (95% CI 5 to 9). We rated the quality of the evidence as low for both primary outcomes. The possible advantage of benzodiazepine was also seen for remission (RR 1.61, 95% CI 1.38 to 1.88) and the endpoint data for social functioning (standardised mean difference (SMD) -0.53, 95% CI -0.65 to -0.42), both with low-quality evidence. We assessed the evidence for the other secondary outcomes as of very low quality. With the exception of the analyses of the change score data for depression (SMD -0.22, 95% CI -0.48 to 0.04) and social functioning (SMD -0.32, 95% CI -0.88 to 0.24), all secondary outcome analyses showed an effect in favour of benzodiazepines compared to placebo. However, the number of dropouts due to adverse effects was higher with benzodiazepines than with placebo (RR 1.58, 95% CI 1.16 to 2.15; low-quality evidence). Furthermore, our analyses of adverse events showed that a higher proportion of participants experienced at least one adverse effect when treated with benzodiazepines (RR 1.18, 95% CI 1.02 to 1.37; low-quality evidence). AUTHORS' CONCLUSIONS: Low-quality evidence shows a possible superiority of benzodiazepine over placebo in the short-term treatment of panic disorders. The validity of the included studies is questionable due to possible unmasking of allocated treatments, high dropout rates, and probable publication bias. Moreover, the included studies were only short-term studies and did not examine the long-term efficacy nor the risks of dependency and withdrawal symptoms. Due to these limitations, our results regarding the efficacy of benzodiazepines versus placebo provide only limited guidance for clinical practice. Furthermore, the clinician's choice is not between benzodiazepines and placebo, but between benzodiazepines and other agents, notably SSRIs, both in terms of ef
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE guidelines: 7. Rating the quality of evidence—inconsistency
Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Glasziou, P., Jaeschke, R., Akl, E. A., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.03.017 · Cited by 2,320
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
Epidemiology of anxiety disorders in the 21st century
Bandelow, B., & Michaelis, S. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.3/bbandelow · Cited by 2,079
GRADE guidelines: 8. Rating the quality of evidence—indirectness
Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Falck-Ytter, Y., Jaeschke, R., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.04.014 · Cited by 1,843
Imputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568
Self-citationStatistics Notes: Detecting skewness from summary information: Table 1
Altman, D. G., & Bland, J. M. (1996) · BMJ · doi:10.1136/bmj.313.7066.1200 · Cited by 1,278
Bijl, R. V., Ravelli, A., & van Zessen, G. (1998) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s001270050098 · Cited by 1,216
Delineation of two drug-responsive anxiety syndromes
Klein, D. F. (1964) · Psychopharmacologia · doi:10.1007/bf02193476 · Cited by 898
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
Kessler, R. C., Chiu, W. T., Jin, R., Ruscio, A. M., Shear, K., & Walters, E. E. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.4.415 · Cited by 795
Benzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Als-Nielsen, B., Chen, W., Gluud, C., & Kjaergard, L. L. (2003) · JAMA · doi:10.1001/jama.290.7.921 · Cited by 746
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Self-citationBallenger, J. C. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290027004 · Cited by 564
Marks, I. M., Swinson, R. P., Başoǧlu, M., Kuch, K., Noshirvani, H., O'Sullivan, G., Lelliott, P. T., Kirby, M., McNamee, G., Sengun, S., et al. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.6.776 · Cited by 478
Bandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., Möller, H.-J., WFSBP Task Force on Mental Disorders in Primary Care, & WFSBP Task Force on Anxiety Disorders, O. A. P. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.667114 · Cited by 428
Imputing response rates from means and standard deviations in meta-analyses
Furukawa, T. A., Cipriani, A., Barbui, C., Brambilla, P., & Watanabe, N. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200501000-00010 · Cited by 337
Self-citationFurukawa, T. A., Guyatt, G. H., & Griffith, L. E. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.72 · Cited by 318
Self-citationPsychological treatment of panic disorder with or without agoraphobia: A meta-analysis
Sánchez-Meca, J., Rosa-Alcázar, A. I., Marín-Martínez, F., & Gómez-Conesa, A. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.08.011 · Cited by 291
Management of benzodiazepine misuse and dependence
Brett, J., & Murnion, B. (2015) · Australian Prescriber · doi:10.18773/austprescr.2015.055 · Cited by 260
Grant, B. F., Hasin, D. S., Stinson, F. S., Dawson, D. A., Goldstein, R. B., Smith, S., Huang, B., & Saha, T. D. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0305 · Cited by 258
Chouinard, G., Annable, L., Fontaine, R., & Solyom, L. (1982) · Psychopharmacology · doi:10.1007/bf00464571 · Cited by 256
de Jonge, P., Roest, A. M., Lim, C. C. W., Florescu, S. E., Bromet, E. J., Stein, D. J., Harris, M., Nakov, V., Caldas-de-Almeida, J. M., Levinson, D., et al. (2016) · Depression and Anxiety · doi:10.1002/da.22572 · Cited by 229
Dell’osso, B., & Lader, M. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2011.11.003 · Cited by 210
Pecknold, J. C. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290043006 · Cited by 204
Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management
Schweizer, E., & Rickels, K. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb05973.x · Cited by 163
Evidence‐based guidelines for interpretation of the Panic Disorder Severity Scale
Furukawa, T. A., Katherine Shear, M., Barlow, D. H., Gorman, J. M., Woods, S. W., Money, R., Etschel, E., Engel, R. R., & Leucht, S. (2009) · Depression and Anxiety · doi:10.1002/da.20532 · Cited by 163
Self-citationHow “blind” are double-blind studies?
Margraf, J., Ehlers, A., Roth, W. T., Clark, D. B., Sheikh, J., Agras, W. S., & Taylor, C. B. (1991) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.59.1.184 · Cited by 135
Schweizer, E. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820130053009 · Cited by 120
Overview of the Cross-National Collaborative Panic Study: I. Efficacy in Short-term Treatment
Klerman, G. L. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290021003 · Cited by 104
Evidence-based pharmacotherapy of panic disorder: an update
Batelaan, N. M., Van Balkom, A. J. L. M., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000800 · Cited by 67
The significance of HPA axis disturbance in panic disorder
Coryell, W., Noyes, R., & Schlechte, J. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90287-4 · Cited by 47
Long‐Term Comparison of Alprazolam, Lorazepam and Placebo in Patients with an Anxiety Disorder
Cohn, J. B., & Wilcox, C. S. (1984) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1984.tb03327.x · Cited by 28
Rynn, M., García-España, F., Greenblatt, D. J., Mandos, L. A., Schweizer, E., & Rickels, K. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000088907.24613.3f · Cited by 23
Cassano, G. B., Toni, C., Petracca, A., Deltito, J., Benkert, O., Curtis, G., Hippius, H., Maier, W., Shera, D., & Klerman, G. (1994) · European Neuropsychopharmacology · doi:10.1016/0924-977x(94)90314-x · Cited by 23
Research works printed but not linked: 204
- Baker, 2003, Correlates of therapeutic response in panic disorder presenting with palpitations: heart rate variability, sleep, and placebo effect, Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie, 48, 381, 10.1177/070674370304800604 · DOI
- Beauclair, 1994, Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response, Journal of Clinical Psychopharmacology, 14, 111, 10.1097/00004714-199404000-00005 · DOI · Paper page
- Carter, 1995, Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy, Journal of Clinical Psychiatry, 56, 202
- Maddock, 1993, Evidence that decreased function of lymphocyte beta adrenoreceptors reflects regulatory and adaptive processes in panic disorder with agoraphobia, American Journal of Psychiatry, 150, 1219, 10.1176/ajp.150.8.1219 · DOI · Paper page
- Albus, 1990, Drug treatment of panic disorder: early response to treatment as a predictor of final outcome, Acta Psychiatrica Scandinavica, 82, 359, 10.1111/j.1600-0447.1990.tb01401.x · DOI
- Andersch, 1997, Panic disorder: a five-year follow-up study in 52 patients, European Journal of Psychiatry, 11, 145
- Andersch, 2003, A 15-year follow-up study of patients with panic disorder, European Psychiatry, 18, 401, 10.1016/j.eurpsy.2003.03.007 · DOI · Paper page
- Andersch, 1991, Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study, Acta Psychiatrica Scandinavica, Supplementum, 365, 18, 10.1111/j.1600-0447.1991.tb03097.x · DOI · Paper page
- Berlanga, 1991, Pharmacologic treatment of panic disorders: comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study, Salud Mental, 14, 1
- Cassano, 1992, Treatment of panic disorder, Advances in Biochemical Psychopharmacology, 47, 449
- Cross National Collaborative Panic Study Second Phase Investigators, 1992, Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo, British Journal of Psychiatry, 160, 191, 10.1192/bjp.160.2.191 · DOI · Paper page
- Curtis, 1993, Maintenance drug therapy of panic disorder, Journal of Psychiatric Research, 27, 127, 10.1016/0022-3956(93)90023-U · DOI
- Deltito, 1991, Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment, Journal of Clinical Psychiatry, 52, 121
- Just, 1991, Alprazolam, imipramine and placebo treatment of panic disorder in Scandinavia. A report from the Cross-National Collaborative Panic Study, second phase: Introduction, Acta Psychiatrica Scandinavica, Supplementum, 83, 5
- Klerman, 1986, The design and conduct of the Upjohn Cross-National Collaborative Panic Study, Psychopharmacology Bulletin, 22, 59
- Leon, 1990, Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia, Acta Psiquiatrica y Psicologica de America Latina, 36, 59
- Maier, 1991, The relevance of agoraphobic syndromes for diagnosis and drug therapy in patients with panic disorder, Verhaltenstherapie, 1, 26, 10.1159/000257936 · doi:10.1159/000257936
- Maier, 1991, Agoraphobia in panic disorder: an indicator of the severity of panic disorder or a distinct diagnostic entity?, Psychiatric Annals, 21, 374, 10.3928/0048-5713-19910601-11 · DOI
- Maier, 1991, Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?, European Archives of Psychiatry and Clinical Neuroscience, 241, 151, 10.1007/BF02219714 · DOI
- Rosenberg, 1991, Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response, Acta Psychiatrica Scandinavica, Supplementum, 365, 46, 10.1111/j.1600-0447.1991.tb03101.x · DOI
- Rosenberg, 1991, Secondary depression in panic disorder: an indicator of severity with a weak effect on outcome in alprazolam and imipramine treatment, Acta Psychiatrica Scandinavica, 365, 39, 10.1111/j.1600-0447.1991.tb03100.x · DOI
- Rosenberg, 1992, Discontinuation effects following short-term or long-term treatment of panic disorder with alprazolam and imipramine, Clinical Neuropharmacology, 15, 621, 10.1097/00002826-199202001-01212 · doi:10.1097/00002826-199202001-01212
- Beitman, 1994, Patient Stage of Change predicts outcome in a panic disorder medication trial, Anxiety, 1, 64, 10.1002/anxi.3070010205 · DOI · Paper page
- Davidson, 1994, Adinazolam sustained-release treatment of panic disorder: a double-blind study, Journal of Clinical Psychopharmacology, 14, 255, 10.1097/00004714-199408000-00005 · doi:10.1097/00004714-199408000-00005
- Maddock, 1993, Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia, Journal of Clinical Psychiatry, 54, 88
- Reid, 1996, Effectiveness of stages of change and adinazolam SR in panic disorder: a neural network analysis, Journal of Anxiety Disorders, 10, 331, 10.1016/0887-6185(96)00014-X · DOI
- Garvey, 1989, The relationship of panic disorder and its treatment outcome to 24-hour urinary MHPG levels, Psychiatry Research, 30, 53, 10.1016/0165-1781(89)90171-6 · DOI
- Klosko, 1990, A comparison of alprazolam and behavior therapy in treatment of panic disorder, Journal of Consulting and Clinical Psychology, 58, 77, 10.1037/0022-006X.58.1.77 · DOI · Paper page
- Klosko, 2016, A comparison of alprazolam and behavior therapy in treatment of panic disorder, 105-21
- Klosko, 1988, Comparison of alprazolam and cognitive-behavior therapy in the treatment of panic disorder. A preliminary report, 10.1007/978-3-642-73543-1_5 · DOI
- Lesser, 1992, Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia, American Journal of Psychiatry, 149, 1556, 10.1176/ajp.149.11.1556 · DOI
- Lydiard, 1992, A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder, Journal of Clinical Psychopharmacology, 12, 96, 10.1097/00004714-199204000-00004 · DOI · Paper page
- Melvin, 1991, Effect of alprazolam on depression in panic disorder, Journal of Clinical Psychopharmacology, 11, 145, 10.1097/00004714-199104000-00020 · doi:10.1097/00004714-199104000-00020
- Jacobs, 1997, The effects of clonazepam on quality of life and work productivity in panic disorder, American Journal of Managed Care, 3, 1187
- Moroz, 1999, Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages, Journal of Clinical Psychiatry, 60, 604, 10.4088/JCP.v60n0907 · DOI · Paper page
- Munjack, 1989, Actual medication versus therapist guesses: in a blind study, how blind is blind?, Journal of Clinical Psychopharmacology, 9, 148, 10.1097/00004714-198904000-00023 · doi:10.1097/00004714-198904000-00023
- Munjack, 1989, Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks, Journal of Clinical Psychopharmacology, 9, 22, 10.1097/00004714-198902000-00005 · DOI · Paper page
- Lopez, 1990, Reduction in urinary free cortisol during benzodiazepine treatment of panic disorder, Psychoneuroendocrinology, 15, 23, 10.1016/0306-4530(90)90043-9 · DOI
- Noyes, 1996, Diazepam versus alprazolam for the treatment of panic disorder, Journal of Clinical Psychiatry, 57, 349
- Noyes, 1991, Controlled discontinuation of benzodiazepine treatment for patients with panic disorder, American Journal of Psychiatry, 148, 517, 10.1176/ajp.148.4.517 · DOI · Paper page
- Pecknold, 1994, A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder, Journal of Clinical Psychopharmacology, 14, 314, 10.1097/00004714-199410000-00005 · DOI · Paper page
- Pecknold, 1993, Panic factor: outcome variable in panic disorder, Journal of Psychiatric Research, 27, 369, 10.1016/0022-3956(93)90064-9 · DOI
- Rosenbaum, 1997, Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group, Journal of Clinical Psychopharmacology, 17, 390, 10.1097/00004714-199710000-00008 · DOI · Paper page
- Savoldi, 1990, Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double-blind study, Current Medical Research and Opinion, 12, 185, 10.1185/03007999009111500 · DOI
- Schweizer, 1992, The use of low-dose intranasal midazolam to treat panic disorder: a pilot study, Journal of Clinical Psychiatry, 53, 19
- Schweizer, 1995, Once-a-day control of panic disorder: evidence from a placebo-controlled trial of alprazolam extended release, Current Therapeutic Research, Clinical & Experimental, 56, 966, 10.1016/0011-393X(95)85102-X · doi:10.1016/0011-393x(95)85102-x
- Schweizer, 1992, A once-a-day, slow-release form of alprazolam for the treatment of panic disorder: a placebo-controlled study, Clinical Neuropharmacology, 15, 26B, 10.1097/00002826-199202001-00049 · doi:10.1097/00002826-199202001-00049
- Schweizer, 1993, Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder, American Journal of Psychiatry, 150, 1210, 10.1176/ajp.150.8.1210 · DOI · Paper page
- Rickels, 1998, Panic disorder: long-term pharmacotherapy and discontinuation, Journal of Clinical Psychopharmacology, 18, 12, 10.1097/00004714-199812001-00004 · DOI · Paper page
- Rickels, 1993, Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper, Archives of General Psychiatry, 50, 61, 10.1001/archpsyc.1993.01820130067010 · DOI · Paper page
- Sheehan, 1993, The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study, Acta Psychiatrica Scandinavica, 88, 1, 10.1111/j.1600-0447.1993.tb03405.x · DOI · Paper page
- Sheikh, 1999, Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo, International Journal of Psychiatry in Medicine, 29, 107, 10.2190/KQEJ-MQJR-VK3D-F3HV · DOI · Paper page
- Clark, 1990, Surreptitious drug use by patients in a panic disorder study, American Journal of Psychiatry, 147, 507, 10.1176/ajp.147.4.507 · DOI · Paper page
- Taylor, 1990, Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial, Journal of Clinical Psychopharmacology, 10, 112, 10.1097/00004714-199004000-00006 · DOI · Paper page
- Pollack, 1993, Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder, Journal of Clinical Psychopharmacology, 13, 257, 10.1097/00004714-199308000-00005 · DOI · Paper page
- Tesar, 1987, Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial, Journal of Clinical Psychiatry, 48, 16
- Tesar, 1991, Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder, Journal of Clinical Psychiatry, 52, 69
- Uhlenhuth, 1989, Response of panic disorder to fixed doses of alprazolam or imipramine, Journal of Affective Disorders, 17, 261, 10.1016/0165-0327(89)90009-8 · DOI
- Valenca, 2000, Double-blind clonazepam vs placebo in panic disorder treatment, Arquivos de Neuro-Psiquiatria, 58, 1025, 10.1590/S0004-282X2000000600008 · DOI · Paper page
- Ananth, 1979, Clobazam in the treatment of anxiety neurosis: a double-blind study, Current Therapeutic Research, Clinical and Experimental, 26, 119
- Greenblatt, 1993, Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder, Archives of General Psychiatry, 50, 715, 10.1001/archpsyc.1993.01820210049006 · DOI
- Noyes, 1988, Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety, Archives of General Psychiatry, 45, 423, 10.1001/archpsyc.1988.01800290037005 · DOI · Paper page
- Pecknold, 1986, Taper withdrawal studies with alprazolam in patients with panic disorder and agoraphobia, Psychopharmacology Bulletin, 22, 173
- Rifkin, 1990, Sequence of improvement in agoraphobia with panic attacks, Journal of Psychiatric Research, 24, 1, 10.1016/0022-3956(90)90020-Q · DOI
- Swinson, 1987, Psychopharmacological treatment of panic disorder and related states: a placebo controlled study of alprazolam, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 11, 105, 10.1016/0278-5846(87)90047-9 · DOI
- Woodman, 1994, Predictors of response to alprazolam and placebo in patients with panic disorder, Journal of Affective Disorders, 30, 5, 10.1016/0165-0327(94)90146-5 · DOI
- Balon, 1991, The changes of thyroid hormone during pharmacological treatment of panic disorder patients, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 15, 595, 10.1016/0278-5846(91)90049-7 · DOI
- Balon, 1993, Changes in appetite and weight during the pharmacological treatment of patients with panic disorder, Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie, 38, 19, 10.1177/070674379303800106 · DOI
- Yeragani, 1992, Imipramine-induced jitteriness and decreased serum iron levels, Neuropsychobiology, 25, 8, 10.1159/000118801 · doi:10.1159/000118801
- Barbosa, 1980, Treatment of neurotic anxiety with clobazam: double-blind clinical trial against placebo, Clinica Terapeutica, 9, 285
- Bernardi, 1988, Double-blind comparative study of alprazolam (Xanax) and amitriptyline in the treatment of anxiety associated with depression, Minerva Psichiatrica, 29, 203
- Bueno, 1988, Anti anxiety activity of buspirone: comparative trial with placebo and diazepam, Jornal Brasileiro de Psiquiatria, 37, 97
- Chen, 1997, Buspirone vs diazepam treatment of anxiety disorders in a double blind study, Zhongyuan Journal of Psychologic Medicine, 3, 146
- Chen, 1998, Buspirone vs diazepam in treating anxiety disorders in a double-blind study, Chinese Journal of New Drugs and Clinical Remedies, 17, 99
- Chen, 2003, Mianserin vs. alprazolam in treating anxiety disorder, Chinese Journal of New Drugs and Clinical Remedies, 22, 405
- Chouinard, 1983, Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study, Psychopharmacology Bulletin, 18, 115
- Cooper, 1990, Beta 2-adrenoceptor antagonism in anxiety, European Neuropsychopharmacology, 1, 75, 10.1016/0924-977X(90)90016-4 · DOI
- Cooper, 1991, A comparison of beta-2-adrenoceptor antagonist (ICI 118,551), diazepam and placebo in the treatment of acute anxiety, Journal of Psychopharmacology, 5, 155, 10.1177/026988119100500210 · DOI
- Csanalosi, 1977, Triflubazam (ORF 8063), a new benzodiazepine in anxiety neurosis, Current Therapeutic Research, Clinical and Experimental, 22, 166
- Cunha, 1988, Anti-anxiety activity of cannabidiol; double-blind, comparative trial with diazepam and placebo, R. Cent. Ci.c Bioméd. Univ. Fed. Uberlândia, 4, 27
- Dager, 1992, Long-term outcome of panic states during double-blind treatment and after withdrawal of alprazolam and placebo, Annals of Clinical Psychiatry, 4, 251, 10.3109/10401239209150457 · DOI
- Dasberg, 1974, The effect of daily oral dosage of diazepam, plasma concentrations and metabolic clearance of diazepam and demethyldiazepam on various constituents of the acute clinical anxiety syndrome, Psychotherapy and Psychosomatics, 24, 113, 10.1159/000286683 · doi:10.1159/000286683
- Davis, 1981, Anxiety: differential diagnosis and treatment from a biologic perspective, Journal of Clinical Psychiatry, 42, 4
- Candia, 2009, Effects of treatment with etizolam 0.5 mg BID on cognitive performance: a 3-week, multicenter, randomized, double-blind, placebo-controlled, two-treatment, three-period, noninferiority crossover study in patients with anxiety disorder, Clinical Therapeutics, 31, 2851, 10.1016/j.clinthera.2009.12.010 · DOI
- Jonghe, 1989, A comparative study of suriclone, lorazepam and placebo in anxiety disorder, Pharmacopsychiatry, 22, 266, 10.1055/s-2007-1014613 · DOI
- Rosa, 1980, Randomized double-blind study of loxapine as compared with diazepam in therapy of patients with anxiety neuroses, Clinica Terapeutica, 95, 127
- Diukova, 1991, Treatment of autonomic crises (attacks of panic), Zhurnal Nevropatologii i Psikhiatrii Imeni S. S. Korsakova, 91, 3
- Diukova, 1993, Treatment of autonomic attacks (panic attacks), Journal of Russian and East European Psychiatry, 26, 22
- Downing, 1978, Prediction of response to chlordiazepoxide and placebo in anxious outpatients: an attempt at replication, Pharmakopsychiatr Neuropsychopharmakol, 11, 207, 10.1055/s-0028-1094580 · doi:10.1055/s-0028-1094580
- Downing, 1979, Nonspecific factors and side effect complaints. Factors affecting the incidence of drowsiness in drug and placebo treated anxious and depressed outpatients, Acta Psychiatrica Scandinavica, 60, 438, 10.1111/j.1600-0447.1979.tb00554.x · DOI
- Downing, 1983, Physician prognosis in relationship to drug and placebo response in anxious and depressed psychiatric outpatients, Journal of Nervous and Mental Disease, 171, 182, 10.1097/00005053-198303000-00009 · doi:10.1097/00005053-198303000-00009
- Dunner, 1986, Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study, Journal of Clinical Psychiatry, 47, 458
- Roy-Byrne, 1989, Relapse and rebound following discontinuation of benzodiazepine treatment of panic attacks: alprazolam versus diazepam, American Journal of Psychiatry, 146, 860, 10.1176/ajp.146.7.860 · DOI · Paper page
- Fava, 1989, Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder, Psychiatry Research, 28, 345, 10.1016/0165-1781(89)90215-1 · DOI
- Filip, 1981, A double-blind, placebo-controlled study with tofizopam in anxiety neurosis, Agressologie, 22, 27
- Franulic, 1989, Clomipramine and diazepam plasma levels in panic disorder and agoraphobia: preliminary findings, Revista Chilena de Neuro-psiquiatria, 27, 101-10
- Greiss, 1980, Double-blind clinical assessment of alprazolam, a new benzodiazepine derivative, in the treatment of moderate to severe anxiety, Journal of Clinical Pharmacology, 20, 693, 10.1002/j.1552-4604.1980.tb01689.x · DOI
- Hare, 1974, Treatment of anxiety and depression: a comparative trial of amitriptyline (Laroxyl) and diazepam (Valium), Clinical Trials Journal, 11, 39
- Hofmeijer-Sevink, 2017, No effects of d-cycloserine enhancement in exposure with response prevention therapy in panic disorder with agoraphobia: a double-blind, randomized controlled trial, Journal of Clinical Psychopharmacology, 37, 531, 10.1097/JCP.0000000000000757 · DOI
- Hu, 2002, A comparative study in psychotherapy and drug in treatment of anxiety disorders, Chinese Journal of Nervous and Mental Diseases, 28, 85
- Huppert, 2004, Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder, American Journal of Psychiatry, 161, 1485, 10.1176/appi.ajp.161.8.1485 · DOI · Paper page
- Kahn, 1986, Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients, Archives of General Psychiatry, 43, 79, 10.1001/archpsyc.1986.01800010081010 · DOI · Paper page
- Kaplan, 2000, Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam, Journal of Clinical Psychopharmacology, 20, 338, 10.1097/00004714-200006000-00008 · DOI
- Keller, 1993, Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo, Journal of Affective Disorders, 28, 27, 10.1016/0165-0327(93)90074-T · DOI
- Leon, 1993, Effect size as a measure of symptom-specific drug change in clinical trials, Psychopharmacology Bulletin, 29, 163
- Pollack, 1994, Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo, Journal of Affective Disorders, 30, 273, 10.1016/0165-0327(94)90134-1 · DOI · Paper page
- Shear, 1995, Pattern of placebo response in panic disorder, Psychopharmacology Bulletin, 31, 273
- Kerry, 1983, Alprazolam in the treatment of neurotic anxiety, Pharmatherapeutica, 3, 451
- Klein, 1988, Nottingham study of neurotic disorder, Lancet, 2, 1015, 10.1016/S0140-6736(88)90760-X · DOI
- Klerman, 1990, Depression and panic anxiety: the effect of depressive co-morbidity on response to drug treatment of patients with panic disorder and agoraphobia, Journal of Psychiatric Research, 24, 27, 10.1016/0022-3956(90)90033-M · DOI
- Knijnik, 1990, Comparative study of cloxazolam and placebo in anxiety neurosis, Jornal Brasileiro de Psiquiatria, 39, 209
- Laakmann, 1980, Double blind study with the benzodiazepine derivative Ka-2547 in outpatients with anxiety neurosis, Arzneimittelforschung, 30, 1233
- Lapierre, 1975, Clinical and physiological assessment of chlorazepate, diazepam and placebo in anxious neurotics, International Journal of Clinical Pharmacology and Biopharmacy, 11, 315
- Lorch, 1995, Treatment of panic disorder: pharmacological versus behavioral therapy?, Pharmacopsychiatry, 28, 199
- Bond, 1995, Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam, Journal of Affective Disorders, 35, 117, 10.1016/0165-0327(95)00053-4 · DOI
- Curran, 1994, Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder, Psychological Medicine, 24, 969, 10.1017/S0033291700029056 · DOI · Paper page
- O'Sullivan, 1994, Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder, British Journal of Psychiatry, 165, 79, 10.1192/bjp.165.1.79 · DOI · Paper page
- O'Sullivan, 1996, Alprazolam withdrawal symptoms in agoraphobia with panic disorder: observations from a controlled Anglo-Canadian study, Journal of Psychopharmacology, 10, 101, 10.1177/026988119601000204 · DOI · Paper page
- Mavissakalian, 1982, Agoraphobia: behavioral and pharmacological treatments, preliminary outcome, and process findings, Psychopharmacology Bulletin, 18, 91
- Michelson, 1985, Psychophysiological outcome of behavioral and pharmacological treatments of agoraphobia, Journal of Consulting and Clinical Psychology, 53, 229, 10.1037/0022-006X.53.2.229 · DOI
- McCurdy, 1978, Studies with oral lorazepam in anxiety neurosis associated with depressive symptomatology, Journal of Clinical Psychiatry, 39, 30
- McEvilly, 1981, Double-blind comparison in parallel groups with nightly single doses of halazepam and placebo, Invest med int, 8, 202
- Mellman, 1986, Withdrawal syndrome with gradual tapering of alprazolam, American Journal of Psychiatry, 143, 1464, 10.1176/ajp.143.11.1464 · DOI · Paper page
- Miretzky, 1992, Combination of alprazolam, antidepressive drugs and cognitive behavior therapy in the treatment of panic disorder, Clinical Neuropharmacology, 15, 536, 10.1097/00002826-199202001-01046 · doi:10.1097/00002826-199202001-01046
- Mueller, 1986, Treatment outcomes of diazepam and oxprenolol with anxiety neurosis patients, 261
- Muncy, 1991, Panic: a comparison of four treatment methods, Dissertation Abstracts International, 51, 6115
- Nair, 1982, Ketazolam in the treatment of anxiety: a standard and placebo controlled study, Current Therapeutic Research, Clinical and Experimental, 31, 679
- Nanivadekar, 1973, A multicenter investigation of lorazepam in anxiety neurosis, Current Therapeutic Research, Clinical and Experimental, 15, 500
- Ogunremi, 1973, Two anti-anxiety drugs: a psychoneuroendocrine study, British Medical Journal, 2, 202, 10.1136/bmj.2.5860.202 · DOI
- Padron, 1974, Comparative clinical evaluation of lorazepam, Schweizerische Rundschau fur Medizin Praxis, 63, 494
- Pasini, 1972, Double blind study on the use of medazepam in ambulatory therapy], Cahiers de Médecine (Europa Medica), 13, 456
- Piedade, 1987, Efficacy of cloxazolam versus placebo in the therapy of anxious status: double-blind controlled study, Jornal Brasileiro de Psiquiatria, 36, 189
- Pollack, 1998, Sertraline in the treatment of panic disorder: A flexible-dose multicenter trial, Archives of General Psychiatry, 55, 1010, 10.1001/archpsyc.55.11.1010 · DOI · Paper page
- Pollack, 2002, Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder, Journal of Psychiatric Research, 36, 229, 10.1016/S0022-3956(02)00010-9 · DOI
- Pols H Alprazolam premedication and 35% CO2 vulnerability in panic patients 8th Congress of the Association of European Psychiatrists London, UK 1996 · doi:10.1016/0924-9338(96)89201-7
- Pols, 1996, Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients, Biological Psychiatry, 40, 913-7, 10.1016/0006-3223(95)00494-7 · DOI
- Porta, 1974, Comparative double-blind clinical trial of SB 5833 and temazapam, Bruxelles Medical, 54, 655
- Predescu, 1969, The "double-blind" procedure in study of the anxiolytic effects of the preparation Wy 3498 (Oxazepam). Evaluation of anxiety states with the Hamilton scale (HS), Neurologia, Psihiatria, Neurochirurgia, 14, 153
- Raffaele, 2002, Therapy of panic attacks in the elderly, Archives of Gerontology and Geriatrics, 35, 295, 10.1016/S0167-4943(02)00111-5 · doi:10.1016/s0167-4943(02)00111-5
- Rapaport, 2000, Alprazolam-XR and neuropsychological function in panic disorder, International Journal of Neuropsychopharmacology, 3, 272
- Rifkin, 1991, The sequence of improvement of the symptoms encountered in patients with panic disorder, Comprehensive Psychiatry, 32, 559, 10.1016/0010-440X(91)90035-B · DOI
- Rizley, 1986, A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder, Psychopharmacology Bulletin, 22, 167
- Saiz-Ruiz, 1992, Personality traits and treatment response in panic disorder, Clinical Neuropharmacology, 15, 533, 10.1097/00002826-199202001-01039 · doi:10.1097/00002826-199202001-01039
- Scieghi, 1986, The intravenous infusion use of chlordemethyldiazepam in neurotic anxiety, Rivista Sperimentale Freniatria, 3, 531
- Sladka, 1979, A placebo-controlled clinical trial with tofizopam in the treament of anxiety neurosis, Therapia Hungarica, 27, 176
- Sladka, 1979, Placebo controlled clinical trial of tofisopam in treatment of anxiety neurosis, Therapia Hungarica, 27, 178
- Sonne, 1986, Alprazolam (Tafil) and bromazepam (Lexotan) in the treatment of anxiety: a randomized, double-blind comparison in psychiatric outpatients, Ugeskrift for Laeger, 148, 1392
- Taylor, 1982, A controlled comparison of relaxation and diazepam in panic disorder, Journal of Clinical Psychiatry, 43, 423
- Telch, 1985, Combined pharmacological and behavioral treatment for agoraphobia, Behaviour Research and Therapy, 23, 325, 10.1016/0005-7967(85)90011-7 · DOI · Paper page
- Terra, 1971, Evaluation of the anti-anxiety activity of lorazepam in ambulatory patients, Jornal Brasileiro de Psiquiatria, 20, 237
- Tesar, 1990, High-potency benzodiazepines for short-term management of panic disorder: the US experience, Journal of Clinical Psychiatry, 51, 4
- Tyrer, 1984, Anxiety in primary care: is short-term drug treatment appropriate?, Journal of Psychiatric Research, 18, 73, 10.1016/0022-3956(84)90048-7 · DOI
- Balkom, 1996, Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia, Journal of Nervous and Mental Disease, 184, 133, 10.1097/00005053-199602000-00015 · DOI
- Boeijen, 2007, First-line treatment of anxiety disorders: a randomized controlled trial, Huisarts en Wetenschap, 50, 315
- Versiani, 1983, Evaluation of the use of cloxazolam in patients with moderate anxiety, Jornal Brasileiro de Psiquiatria, 32, 27
- Wiesner, 1993, Bretazenil: neuroendocrinological profile of a partial benzodiazepine agonist in patients suffering from panic disorder with agoraphobia, Pharmacopsychiatry, 26, 212
- Zmorski, 1985, [ Clinical experiences with the new-generation anxiolytic agent cloxazolam: a double-blind study. ] Klinische Erfahrungen mit dem Anxiolytikum der neuen Generation: CloxazolamEine Doppelblindstudie, Schweizerische Rundschau fur Medizin Praxis, 74, 728
- Bernik, 1983, Therapeutic of anxiety: a double blind clinical trial between alprazolam, oxazepam and placebo, RBM Psiquiatr, 1983, 176-89
- Ciraulo, 1990, The relationship of alprazolam dose to steady-state plasma concentrations, Journal of Clinical Psychopharmacology, 10, 27, 10.1097/00004714-199002000-00005 · DOI
- Fisekovic, 2005, Sertraline and alprazolam in the treatment of panic disorder, Bosnian Journal of Basic Medical Sciences, 5, 78-81, 10.17305/bjbms.2005.3292 · doi:10.17305/bjbms.2005.3292
- Valenca, 2003, Therapeutic response to benzodiazepine in panic disorder subtypes, Revista Paulista de Medicina (Sao Paulo Medical Journal), 121, 77, 10.1590/S1516-31802003000200009 · DOI
- American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders
- American Psychiatric Association, 2009, American Psychiatric Association Practice Guideline for the Treatment of Panic Disorder, 10.1176/appi.books.9780890423905.154688 · DOI
- American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders (DSM-5), 10.1176/appi.books.9780890425596 · DOI · Paper page
- Ballenger, 1998, Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety, Journal of Clinical Psychiatry, 59, 47
- Bandelow, 2006, What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?, Journal of Clinical Psychiatry, 67, 1428, 10.4088/JCP.v67n0914 · DOI · Paper page
- Bhandari, 2004, Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials, Canadian Medical Association Journal, 170, 477
- Bighelli, 2016, Antidepressants and benzodiazepines for panic disorder in adults, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD011567.pub2 · DOI
- Bighelli, 2018, Antidepressants versus placebo for panic disorder in adults, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD010676.pub2 · DOI · Paper page
- Boissel, 1999, The problem of therapeutic efficacy indices. Comparison of the indices and their use, Therapie, 54, 405
- Boyer, 1995, Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis, International Clinical Psychopharmacology, 10, 45, 10.1097/00004850-199503000-00006 · DOI · Paper page
- Bruce, 2003, Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?, American Journal of Psychiatry, 160, 1432, 10.1176/appi.ajp.160.8.1432 · DOI · Paper page
- Buchkowsky, 2004, Industry sponsorship and authorship of clinical trials over 20 years, Annals of Pharmacotherapy, 38, 579, 10.1345/aph.1D267 · DOI · Paper page
- Cameron, 2007, Reduced gamma-aminobutyric acid(A)-benzodiazepine binding sites in insular cortex of individuals with panic disorder, Archives of General Psychiatry, 64, 793, 10.1001/archpsyc.64.7.793 · DOI · Paper page
- Clark, 1993, An overview of the cognitive theory and treatment of panic disorder, Applied and Preventive Psychology, 2, 131, 10.1016/S0962-1849(05)80119-2 · DOI
- Clum, 1993, A meta-analysis of treatments for panic disorder, Journal of Consulting and Clinical Psychology, 61, 317, 10.1037/0022-006X.61.2.317 · DOI · Paper page
- Dresler, 2013, Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder, Journal of Neural Transmission (Vienna), 120, 3, 10.1007/s00702-012-0811-1 · DOI · Paper page
- Fujii, 2015, Dependence on benzodiazepines in patients with panic disorder: a cross-sectional study, Psychiatry and Clinical Neurosciences, 69, 93, 10.1111/pcn.12203 · DOI
- Goisman, 1995, DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis, American Journal of Psychiatry, 152, 1438, 10.1176/ajp.152.10.1438 · DOI · Paper page
- Gorman, 2000, Neuroanatomical hypothesis of panic disorder, revised, American Journal of Psychiatry, 157, 493, 10.1176/appi.ajp.157.4.493 · DOI · Paper page
- Hemington, 2015, The periaqueductal gray and descending pain modulation: why should we study them and what role do they play in chronic pain?, Journal of Neurophysiology, 114, 2080, 10.1152/jn.00998.2014 · DOI
- Higgins, 2011, Cochrane Handbook for Systematic Reviews of Interventions
- Imai, 2016, Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD011170.pub2 · DOI · Paper page
- King, 2008, Prevalence of common mental disorders in general practice attendees across Europe, British Journal of Psychiatry, 192, 362, 10.1192/bjp.bp.107.039966 · DOI · Paper page
- Lavori, 1992, Clinical trials in psychiatry: should protocol deviation censor patient data?, Neuropsychopharmacology, 6, 39
- Lavori, 1995, A multiple imputation strategy for clinical trials with truncation of patient data, Statistics in Medicine, 14, 1913, 10.1002/sim.4780141707 · DOI · Paper page
- Malizia, 1998, Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study, Archives of General Psychiatry, 55, 715, 10.1001/archpsyc.55.8.715 · DOI · Paper page
- Margraf, 1991, How "blind" are double-blind studies?, Journal of Consulting and Clinical Psychology, 59, 184, 10.1037/0022-006X.59.1.184 · DOI · Paper page
- Mattick, 1990, Treatment of panic and agoraphobia. An integrative review, Journal of Nervous and Mental Disease, 178, 567, 10.1097/00005053-199009000-00003 · DOI · Paper page
- Moher, 2009, Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement, PLOS Medicine, 6, e1000097, 10.1371/journal.pmed.1000097 · DOI · Paper page
- Munjack, 1989, Actual medication versus therapist guesses: in a blind study, how blind is blind?, Journal of Clinical Psychopharmacology, 9, 148, 10.1097/00004714-198904000-00023 · doi:10.1097/00004714-198904000-00023
- National Institute for Health and Care Excellence, 2011, Generalised Anxiety Disorder and Panic Disorder (With or Without Agoraphobia) in Adults [CG113]
- Preti, 2016, Prevalence, impact and treatment of generalised anxiety disorder in bipolar disorder: a systematic review and meta-analysis, Evidence-Based Mental Health, 19, 73, 10.1136/eb-2016-102412 · DOI · Paper page
- Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014
- Rosenberg, 1994, Prediction of placebo response in panic disorder: A short review, Nordic Journal of Psychiatry, 48, 153, 10.3109/08039489409081352 · DOI
- Schallemberger, 2016, Assessment of dependence and anxiety among benzodiazepine users in a provincial municipality in Rio Grande do Sul, Brazil, Trends in Psychiatry and Psychotherapy, 27, 63, 10.1590/2237-6089-2015-0041 · DOI
- Serrano-Blanco, 2010, Prevalence of mental disorders in primary care: results from the diagnosis and treatment of mental disorders in primary care study (DASMAP), Social Psychiatry and Psychiatric Epidemiology, 45, 201, 10.1007/s00127-009-0056-y · DOI · Paper page
- Starcevic, 2009, Anxiety Disorders in Adults: a Clinical Guide, 10.1093/oso/9780195369250.001.0001 · DOI · Paper page
- Stein, 2010, Pharmacologic treatment of panic disorder, Current Topics in Behavioral Neurosciences, 2, 469, 10.1007/7854_2009_35 · DOI
- Viechtbauer, 2010, Conducting meta-analyses in R with themetafor package, Journal of Statistical Software, 36, 1, 10.18637/jss.v036.i03 · DOI · Paper page
200 of 204 shown
Cited by
Metaprop: a Stata command to perform meta-analysis of binomial data
Nyaga, V. N., Arbyn, M., & Aerts, M. (2014) · Archives of Public Health · doi:10.1186/2049-3258-72-39 · Cited by 2,139
Penninx, B. W., Pine, D. S., Holmes, E. A., & Reif, A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00359-7 · Cited by 740
Szuhany, K. L., & Simon, N. M. (2022) · JAMA · doi:10.1001/jama.2022.22744 · Cited by 541
Diagnostic procedures in autism spectrum disorders: a systematic literature review
Falkmer, T., Anderson, K., Falkmer, M., & Horlin, C. (2013) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-013-0375-0 · Cited by 409
Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Guina, J., & Merrill, B. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020017 · Cited by 253
Metadata
- Authors
- Breilmann, J., Girlanda, F., Guaiana, G., Barbui, C., Cipriani, A., Castellazzi, M., Bighelli, I., Davies, S. J., Furukawa, T. A., & Koesters, M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2019-03-28
- Volume
- 3
- Pages
- CD010677-CD010677
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1488774684
- Cited by
- 98
- References
- 36
- FWCI
- 11.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.